| Document |
Document Title |
|
WO/2023/060811A1 |
Disclosed in the present invention are a fluralaner intermediate and a method for preparing fluralaner thereby. The fluralaner intermediate-5 is aaa. A synthetic route comprises: using m-xylene as a starting raw material, performing halo...
|
|
WO/2023/054702A1 |
The present invention addresses the problem of providing an industrially preferable method for producing an aldehyde represented by formula (3) or (4): (3) (4). The present invention produces a compound of formula (3) or compound of fo...
|
|
WO/2023/047416A1 |
The present invention relates to a novel process for preparation of an isoxazole compound of formula (I) by reacting a compound of formula (II) with a compound of formula (III). wherein, n is 0, 1 or 2; 10 R1, R2, R3 and R4 are independe...
|
|
WO/2023/031061A1 |
The present invention relates to a process for the preparation of a compound of formula (I) or an enriched composition comprising a compound of formula (I), by reacting a compound of formula (II),with hydroxylamine or its salt, a base, a...
|
|
WO/2023/031199A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of the s...
|
|
WO/2023/025277A1 |
Provided are an aromatic ring-containing biological antagonist as represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the prepa...
|
|
WO/2023/028074A1 |
Disclosed are 4-hydroxylphenyl substituted carbocycles and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat d...
|
|
WO/2023/020274A1 |
The present invention belongs to the technical field of pesticides; and specifically relates to a 3-isoxazolidinone compound and a preparation method therefor, and a herbicidal composition and the use thereof. The 3-isoxazolidinone compo...
|
|
WO/2023/023242A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein Q1, Q2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 an...
|
|
WO/2023/015395A1 |
Provided are beneficial and therapeutic Amanita muscaria compositions. In some embodiments, the provided /L muscaria compositions comprise A. muscaria extracts. In some embodiments, the provided A muscaria compositions comprise one or mo...
|
|
WO/2023/010203A1 |
This invention relates to the extraction of psychoactive compounds from psychedelic organisms for use in medicine. Raw psychedelic organisms are dried and pulverized. The psychoactive compounds are extracted using a solvent to result in ...
|
|
WO/2023/012821A1 |
The present invention provides a process for the preparation of a compound of Formula I, wherein, # indicates the attachment to isoxazoline ring and * indicates the attachment to the carbonyl carbon, The present invention particularly pr...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/007429A1 |
The present invention discloses a process for the preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds of formula (I) wherein, R1, R2, Ra, Q, n and m are as defined in the description, and interme...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/274870A1 |
The invention relates to a novel method for producing isoxazolinecarboxylic acid derivatives of formula (I).
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/263573A1 |
The present invention provides compounds of formula (I) which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and methods of usi...
|
|
WO/2022/266244A1 |
The present disclosure provides crystalline forms of 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S
)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluo
romethyl)-4H-isoxazol-3-yl]benzamide, methods of preparing the...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/253645A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2022/253959A1 |
The present invention relates to compounds, pharmaceutical compositions and medicaments suitable for use in the prevention and/or treatment of neurodegenerative disorders, such as for example demyelinating diseases. These compounds have ...
|
|
WO/2022/246557A1 |
There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Major Depressive Disorder (MDD). There is also provided combination therapies and therapeutic methods that include inter...
|
|
WO/2022/242688A1 |
A crystal form of a cyano-substituted macrocyclic compound (I) and a preparation method therefor. Further provided is an application of the crystal form in the preparation of a drug for treating solid tumors caused by abnormal expression...
|
|
WO/2022/243983A1 |
The present invention provides fused isoxazolyl compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases or disorders dependent upon KAT6A in a mammal. The ...
|
|
WO/2022/238707A1 |
The present invention relates to a group of resorcinol derivatives as a pharmaceutically active compounds and methods of preparation thereof. Resorcinol derivatives have been used to treat various diseases and disorders. While such treat...
|
|
WO/2022/236118A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 ...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/226660A1 |
The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of an isoxazoline such as fluralaner, a composition c...
|
|
WO/2022/206010A1 |
Disclosed in the present invention is a simple preparation method for isoxazolines, comprising: using aldehyde, p-toluenesulfonyl hydrazide, olefin, and tert-butyl nitrite as a substrate, using copper chloride as a catalyst, using tetram...
|
|
WO/2022/204288A1 |
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. ...
|
|
WO/2022/193187A1 |
Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/194240A1 |
Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/187974A1 |
Disclosed herein are methods of muscimol extraction from Amanita mushrooms, and more particularly, enhanced muscimol extraction processes from Amanita muscaria, including by distillation, refluxing, and pressing, including processes that...
|
|
WO/2022/174882A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl carbamate...
|
|
WO/2022/178283A1 |
Disclosed are compounds and methods for treating tauopathy.
|
|
WO/2022/174256A1 |
The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present...
|
|
WO/2022/171472A1 |
The invention relates to isoxazoline compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for...
|
|
WO/2022/166990A1 |
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...
|
|
WO/2022/155037A1 |
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...
|
|
WO/2022/147448A1 |
Disclosed herein are compounds that can be used as Farnesoid X Receptor (FXR) agonists, compositions containing these compounds and methods of use thereof.
|
|
WO/2022/145408A1 |
The present invention provides compounds that have a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity, and pharmaceutically acceptable salts thereof, and also provides a serotonin 5-HT2A receptor antagonist and/or inv...
|
|
WO/2022/134146A1 |
The present invention relates to a novel FXR agonist having a pyrazine structure, a preparation method therefor and the use thereof, and in particular relates to a compound as represented by the following general formula (I), or a hydrat...
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/127564A1 |
The present invention relates to the technical field of herbicides, and specifically to isoxazoline-containing pyridine biphenyl compounds, a preparation method therefor and the use thereof. The present invention specifically provides co...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129041A1 |
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
